Galmed Pharma (GLMD) Misses Q4 EPS by 12c

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.48), $0.12 worse than the analyst estimate of ($0.36).

• For the three and twelve months ended December 31, 2020, the Company recorded a net loss of $10.3 million and $28.8 million or $0.48 and $1.35 per share, respectively, compared with a net loss of $8.3 million and $20.5 million, or $0.39 and $0.97 per share, for the three and twelve months ended December 31, 2019.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance